Article Text
Statistics from Altmetric.com
WHAT IS ALREADY KNOWN ON THIS TOPIC
According to statistical reports, nearly 45% of patients with cardiovascular disease (CVD) struggle with major depressive symptoms. Based on WHO estimates, the prevalence of clinical depression in people suffering from CVD was reported up to 9% worldwide.
WHAT THIS STUDY ADDS
The total number of patients with CVD was reported to be 64 068 167, of which 3 687 872 suffered from depression. According to our analysis, the prevalence rate of depression in patients with cardiovascular disease was estimated at 18.4% (95% CI 15% to 22.3%).
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
Regular screening for depression in patients with CVD should be a key priority in treatment programmes at least on a yearly basis, as a major risk factor for the disease.
Introduction
In accordance with the WHO, people with mental health issues including depression are regarded as a vulnerable group who should be given special attention in health promotion and preventive programmes. These vulnerable people often suffer from higher rates of discrimination and reduced access to health and social services, which ultimately might negatively affect their quality of life.1 2 It has been noted that when cardiac disease and depression occur simultaneously in the same individual, the prognosis of both diseases will intensify and accelerate.3 According to statistical reports, nearly 45% of patients with cardiovascular disease (CVD) struggle with major depressive symptoms.4 Research has also found that depression is more common in cardiac patients and plays as a crucial risk factor for cardiac morbidity and mortality.5
Another justification for the association between depression and CVD is adherence to pharmacological and medical treatments which is recommended to cardiac patients. In fact, some of the features of depression contribute to the ideas and feelings of patients towards the disease, tendency to heal, confidence and trust in healthcare professionals and, most importantly, medical adherence, which ultimately affect the progression of the …
Footnotes
Contributors Conception and design of study: SRaf, AG, FPK and ZN; acquisition of data: SRaf, FPK, SRao, MSa, FB, NR, EsVS, MSh, ZHK and FR; analysis and/or interpretation of data: AG; drafting the manuscript: AJB, AG, MM and MD; revising the manuscript critically for important intellectual content: ZM, SY, AG, FPK, SRaf, AB and MM; approval of the version of the manuscript to be published: SRaf, AG and SRao,
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.